UA87437C2 - Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии - Google Patents

Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии

Info

Publication number
UA87437C2
UA87437C2 UA20041109649A UA20041109649A UA87437C2 UA 87437 C2 UA87437 C2 UA 87437C2 UA 20041109649 A UA20041109649 A UA 20041109649A UA 20041109649 A UA20041109649 A UA 20041109649A UA 87437 C2 UA87437 C2 UA 87437C2
Authority
UA
Ukraine
Prior art keywords
replacement therapy
hormone replacement
hypertension
treatment
women receiving
Prior art date
Application number
UA20041109649A
Other languages
English (en)
Ukrainian (uk)
Inventor
Адель Х. Карара
Original Assignee
Бристол-Майерс Сквибб Компани Айседжен Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани Айседжен Инк filed Critical Бристол-Майерс Сквибб Компани Айседжен Инк
Publication of UA87437C2 publication Critical patent/UA87437C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается новых циклоалкильных соединений, которые могут применяться в качестве ингибиторов функции калиевых каналов (в частности, в качестве ингибиторов подсемейства КІ потенциал-управляемых K+-каналов, а именно в качестве ингибиторов каналов К1,5, которые были связаны с сверхбыстро активирующим К+-потоком Ізадержанного выпрямителя), применения этих соединений в профилактике и лечении аритмии и І-ассоциированных расстройств, а также фармацевтических композиций, которые содержат такие соединения.
UA20041109649A 2002-04-26 2003-03-24 Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии UA87437C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37543902P 2002-04-26 2002-04-26

Publications (1)

Publication Number Publication Date
UA87437C2 true UA87437C2 (ru) 2009-07-27

Family

ID=29270642

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041109649A UA87437C2 (ru) 2002-04-26 2003-03-24 Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии

Country Status (23)

Country Link
US (1) US20040034001A1 (ru)
EP (2) EP1982719A1 (ru)
JP (1) JP2005528408A (ru)
KR (1) KR20040104632A (ru)
CN (1) CN1649596A (ru)
AU (2) AU2003239162A1 (ru)
BR (1) BR0309780A (ru)
CA (1) CA2483554A1 (ru)
CR (1) CR7571A (ru)
EC (1) ECSP045456A (ru)
HK (1) HK1079997A1 (ru)
HR (1) HRP20041121A2 (ru)
IL (1) IL164808A0 (ru)
ME (1) MEP35908A (ru)
MX (1) MXPA04010682A (ru)
NO (1) NO20045147L (ru)
NZ (1) NZ548754A (ru)
PL (1) PL372055A1 (ru)
RS (1) RS93804A (ru)
RU (1) RU2373940C2 (ru)
UA (1) UA87437C2 (ru)
WO (1) WO2003090755A1 (ru)
ZA (1) ZA200409548B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE102004016779A1 (de) * 2004-04-01 2006-01-19 Schering Ag Drospirenonhaltige Zubereitungen zur transdermalen Anwendung
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
US20090035373A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same
US20090035374A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
US20130137664A1 (en) * 2010-04-15 2013-05-30 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US5001113A (en) 1987-10-14 1991-03-19 Merck & Co., Inc. Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US6083528A (en) 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR0156678B1 (ko) 1996-01-11 1998-10-15 이상윤 안지오텐신 전환효소 저해제
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
UA74141C2 (ru) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтическая композиция на основе тонкодисперсного эплеренона (варианты), способ ее получения и способ лечения расстройств, опосредованных альдостероном (варианты)
SI1214076T1 (en) * 1999-08-31 2004-06-30 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
ATE442147T1 (de) * 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins

Also Published As

Publication number Publication date
KR20040104632A (ko) 2004-12-10
HRP20041121A2 (en) 2005-02-28
NO20045147L (no) 2005-01-18
RU2373940C2 (ru) 2009-11-27
ECSP045456A (es) 2005-01-28
RS93804A (sr) 2006-10-27
MEP35908A (en) 2011-02-10
CR7571A (es) 2006-02-07
PL372055A1 (en) 2005-07-11
IL164808A0 (en) 2005-12-18
AU2003239162A1 (en) 2003-11-10
BR0309780A (pt) 2005-03-22
JP2005528408A (ja) 2005-09-22
NZ548754A (en) 2008-06-30
CA2483554A1 (en) 2003-11-06
EP1499323A1 (en) 2005-01-26
RU2004134571A (ru) 2005-07-10
CN1649596A (zh) 2005-08-03
AU2008203497A1 (en) 2008-08-28
ZA200409548B (en) 2010-05-26
US20040034001A1 (en) 2004-02-19
MXPA04010682A (es) 2004-12-13
EP1982719A1 (en) 2008-10-22
WO2003090755A1 (en) 2003-11-06
HK1079997A1 (zh) 2006-04-21

Similar Documents

Publication Publication Date Title
UA87437C2 (ru) Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии
PL323729A1 (en) Skin sticking plaster and method of administering sole 17-deacetyl norgestimate or together with estrogen
GB0001309D0 (en) Valve arrangement
TR200200406T2 (tr) Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
GB0010683D0 (en) Cancer therapy
CN204909832U (zh) 腮腺术后区伤口加压装置
SE9902597D0 (sv) New use
EA200200943A1 (ru) Гормональная терапия рака молочной железы
Chakalova et al. Cancer burden of breast and gynecological cancers in Bulgaria: epidemiology and clinical aspects
DE60202954D1 (de) Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
CN2733923Y (zh) 一种内裤
WO2003097690A3 (en) Pth derivatives resistant to skin proteases
AU9627898A (en) Tightening and/or reducing the size of body parts containing fat cells
AR039477A1 (es) Terapia de reemplazo hormonal
RU2008149412A (ru) Применение дроспиренона для предотвращения высокого кровяного давления у пациентов с прегипертонией
AU2003209091A1 (en) Occluding and stablizing medical device
AU2450900A (en) Therapeutic nucleoside compound
UA38912A (ru) Способ профилактики и лечения фетоплацентарной недостаточности у беременных женщин с внутриматочной гибелью плода в анамнезе
UA74495C2 (ru) Способ хирургического лечения неспецифических полных экстрасфинктерных свищей прямой кишки
UA36207A (ru) Способ профилактики послеродовых септических заболеваний у вич-инфицированных женщин
UA29211A (ru) Способ прогнозирования раннего климакса у женщин
GB0208129D0 (en) Method of treatment
UA32213A (ru) Способ формирования временной искусственной кишечной фистулы